Spikimm and Institut Pasteur Announce That SPKM001, A Next-generation, Highly Potent Anti-SARS-CoV-2 Human Monoclonal Antibody, Effectively Neutralizes the Delta and Delta Plus Variants
Retrieved on:
Mercredi, septembre 8, 2021
SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the SARS-CoV-2 Spike protein.
Key Points:
- SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the SARS-CoV-2 Spike protein.
- SpikImm has recently signed an exclusive worldwide license agreement with the Institut Pasteur for the development of anti-SARS-CoV-2 (Covid-19) monoclonal antibodies (mAbs), including SPKM001.
- Delta Plus, which the World Health Organization also lists as a variant of concern, was first detected in the U.K. in June.
- It has since been found in several other countries, including the U.S., India, China, Russia, and Japan.